3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
53
Sarcoma
5
Lymphoid
4
Myeloid
2
Gastrointestinal
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Ovarian Neoplasms
359
Endometrial Neoplasms
207
Uterine Cervical Neoplasms
187
Breast Neoplasms
109
Fallopian Tube Neoplasms
96
Colorectal Neoplasms
83
Carcinoma, Non-Small-Cell Lung
76
Neoplasms
65
Pancreatic Neoplasms
59
Stomach Neoplasms
55
Neoplasm Metastasis
51
Prostatic Neoplasms
50
Lung Neoplasms
46
Melanoma
43
Carcinoma, Ovarian Epithelial
41
Triple Negative Breast Neoplasms
38
Squamous Cell Carcinoma of Head and Neck
36
Esophageal Neoplasms
35
Carcinoma, Renal Cell
35
Colonic Neoplasms
31
Urinary Bladder Neoplasms
30
Peritoneal Neoplasms
29
Head and Neck Neoplasms
28
Vulvar Neoplasms
26
Uterine Neoplasms
26
Carcinoma, Hepatocellular
26
Carcinoma, Transitional Cell
24
Small Cell Lung Carcinoma
23
Sarcoma
20
Rectal Neoplasms
19
Interventions
trastuzumab deruxtecan
1
Temozolomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Astrocytoma
×
Gynecologic
×
90 days
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled